gossypol has been researched along with Carcinoma, Squamous Cell in 10 studies
Gossypol: A dimeric sesquiterpene found in cottonseed (GOSSYPIUM). The (-) isomer is active as a male contraceptive (CONTRACEPTIVE AGENTS, MALE) whereas toxic symptoms are associated with the (+) isomer.
Carcinoma, Squamous Cell: A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Given the evidence of activity in xenograft models, treatment with AT-101 in combination with docetaxel is a therapeutic doublet of interest in metastatic head and neck squamous cell carcinoma." | 2.82 | A phase II trial of the BCL-2 homolog domain 3 mimetic AT-101 in combination with docetaxel for recurrent, locally advanced, or metastatic head and neck cancer. ( Bellile, E; Bradford, C; Carey, TE; Chepeha, DB; Eisbruch, A; Jackson, TL; Malloy, K; McKean, E; McLean, S; Moyer, J; Nör, JE; Pearson, AT; Prince, M; Sacco, AG; Shuman, A; Spector, ME; Sukari, A; Swiecicki, PL; Taylor, JM; Wang, S; Wolf, GT; Worden, FP, 2016) |
| " For the pharmacokinetic analysis, plasma AT-101 levels were measured by HPLC in blood samples collected from patients enrolled in our clinical phase I/II study." | 2.80 | Targeting anti-apoptotic Bcl-2 by AT-101 to increase radiation efficacy: data from in vitro and clinical pharmacokinetic studies in head and neck cancer. ( Dubbelman, R; Hoebers, FJ; Kuipers, GK; Lafleur, MV; Slotman, BJ; Stoter, TR; van den Brekel, MW; Verheij, M; Zerp, SF, 2015) |
| " Unlike trials with continuous daily dosing of AT-101, no cases of small bowel obstruction were reported." | 2.76 | Double-blind, placebo-controlled, randomized phase 2 study of the proapoptotic agent AT-101 plus docetaxel, in second-line non-small cell lung cancer. ( Holmlund, JT; Karaseva, NA; Leopold, L; Luft, AV; Orlov, SV; Popovych, O; Ready, N; Wood, BA, 2011) |
| "Despite intensive investigation, oral squamous cell carcinomas (OSCC) represent a clinical challenge resulting in significant morbidity and mortality." | 1.42 | Mcl-1 is an important therapeutic target for oral squamous cell carcinomas. ( Das, SK; Dash, R; Fisher, PB; Maji, S; Panda, S; Pattanaik, L; Pellecchia, M; Quinn, BA; Samal, SK; Sarkar, D, 2015) |
| " Thus, we hypothesized that BH3-mimetic drugs that antagonize Bcl-2 family proteins may exert a greater efficacy when dosed metronomically." | 1.38 | Metronomic dosing of BH3 mimetic small molecule yields robust antiangiogenic and antitumor effects. ( Dong, Z; Imai, A; Krishnamurthy, S; Light, E; Nör, JE; Visioli, F; Wang, S; Worden, F; Zeitlin, BD; Zhang, Z, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 5 (50.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Haasler, L | 1 |
| von Montfort, C | 1 |
| Kondadi, AK | 1 |
| Golombek, M | 1 |
| Ebbert, L | 1 |
| Wenzel, CK | 1 |
| Stahl, W | 1 |
| Reichert, AS | 1 |
| Brenneisen, P | 1 |
| Maji, S | 1 |
| Samal, SK | 1 |
| Pattanaik, L | 1 |
| Panda, S | 1 |
| Quinn, BA | 1 |
| Das, SK | 1 |
| Sarkar, D | 1 |
| Pellecchia, M | 1 |
| Fisher, PB | 1 |
| Dash, R | 1 |
| Zerp, SF | 1 |
| Stoter, TR | 1 |
| Hoebers, FJ | 1 |
| van den Brekel, MW | 1 |
| Dubbelman, R | 1 |
| Kuipers, GK | 1 |
| Lafleur, MV | 1 |
| Slotman, BJ | 1 |
| Verheij, M | 1 |
| Swiecicki, PL | 1 |
| Bellile, E | 1 |
| Sacco, AG | 1 |
| Pearson, AT | 1 |
| Taylor, JM | 1 |
| Jackson, TL | 1 |
| Chepeha, DB | 1 |
| Spector, ME | 1 |
| Shuman, A | 1 |
| Malloy, K | 1 |
| Moyer, J | 1 |
| McKean, E | 1 |
| McLean, S | 1 |
| Sukari, A | 1 |
| Wolf, GT | 1 |
| Eisbruch, A | 1 |
| Prince, M | 1 |
| Bradford, C | 1 |
| Carey, TE | 4 |
| Wang, S | 5 |
| Nör, JE | 2 |
| Worden, FP | 1 |
| Ready, N | 1 |
| Karaseva, NA | 1 |
| Orlov, SV | 1 |
| Luft, AV | 1 |
| Popovych, O | 1 |
| Holmlund, JT | 1 |
| Wood, BA | 1 |
| Leopold, L | 1 |
| Imai, A | 1 |
| Zeitlin, BD | 1 |
| Visioli, F | 1 |
| Dong, Z | 1 |
| Zhang, Z | 1 |
| Krishnamurthy, S | 1 |
| Light, E | 1 |
| Worden, F | 1 |
| Oliver, CL | 1 |
| Bauer, JA | 2 |
| Wolter, KG | 2 |
| Ubell, ML | 1 |
| Narayan, A | 1 |
| O'Connell, KM | 1 |
| Fisher, SG | 1 |
| Wu, X | 1 |
| Ji, M | 1 |
| Bradford, CR | 3 |
| Konac, E | 1 |
| Ekmekci, A | 1 |
| Yurtcu, E | 1 |
| Ergun, MA | 1 |
| Trask, DK | 1 |
| Kumar, B | 2 |
| Los, G | 1 |
| Castro, J | 1 |
| Lee, JS | 1 |
| Chen, J | 2 |
| Wang, SJ | 1 |
| Henson, BS | 1 |
| Griffith, KA | 1 |
| D'Silva, NJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double Blind, Placebo-controlled Multiple-center Phase III Trial of Gossypol Combined With Docetaxel and Cisplatin Scheme in Advanced Non Small-cell Lung Cancers With APE1 High Expression[NCT01977209] | Phase 3 | 204 participants (Anticipated) | Interventional | 2013-09-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for gossypol and Carcinoma, Squamous Cell
| Article | Year |
|---|---|
Targeting anti-apoptotic Bcl-2 by AT-101 to increase radiation efficacy: data from in vitro and clinical pharmacokinetic studies in head and neck cancer.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Line | 2015 |
A phase II trial of the BCL-2 homolog domain 3 mimetic AT-101 in combination with docetaxel for recurrent, locally advanced, or metastatic head and neck cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squam | 2016 |
Double-blind, placebo-controlled, randomized phase 2 study of the proapoptotic agent AT-101 plus docetaxel, in second-line non-small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Aged; Antineoplastic Combined Chemotherapy Prot | 2011 |
7 other studies available for gossypol and Carcinoma, Squamous Cell
| Article | Year |
|---|---|
Involvement of necroptosis in the selective toxicity of the natural compound (±) gossypol on squamous skin cancer cells in vitro.
Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Gossypol; Humans; Necroptosis; Skin Neoplasms | 2023 |
Mcl-1 is an important therapeutic target for oral squamous cell carcinomas.
Topics: 4-Nitroquinoline-1-oxide; Animals; Apoptosis; Apoptosis Regulatory Proteins; Autophagy-Related Prote | 2015 |
Metronomic dosing of BH3 mimetic small molecule yields robust antiangiogenic and antitumor effects.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Line, Tumor; | 2012 |
In vitro effects of the BH3 mimetic, (-)-gossypol, on head and neck squamous cell carcinoma cells.
Topics: Apoptosis; bcl-X Protein; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Prolif | 2004 |
An in vitro study of cytotoxic effects of gossypol on human epidermoid larynx carcinoma cell line (HEp-2).
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Screening Assays, | 2005 |
Reversal of cisplatin resistance with a BH3 mimetic, (-)-gossypol, in head and neck cancer cells: role of wild-type p53 and Bcl-xL.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cisplatin; Drug Resistance, Neoplasm; Go | 2005 |
(-)-gossypol inhibits growth and promotes apoptosis of human head and neck squamous cell carcinoma in vivo.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-X Protein; Carcinoma, Squamous Cell; Cell | 2006 |